MARKET

KURA

KURA

Kura Oncology Inc
NASDAQ
10.86
-0.03
-0.28%
After Hours: 10.95 +0.09 +0.83% 18:52 07/17 EDT
OPEN
10.62
PREV CLOSE
10.89
HIGH
10.99
LOW
10.50
VOLUME
814.98K
TURNOVER
--
52 WEEK HIGH
12.49
52 WEEK LOW
5.45
MARKET CAP
964.09M
P/E (TTM)
-3.2437
1D
5D
1M
3M
1Y
5Y
1D
Is Kura Oncology (KURA) Turning Darlifarnib Into a Foundational Precision Combo Platform?
Simply Wall St · 8h ago
A Fresh Look At Syndax Pharmaceuticals
Seeking Alpha · 4d ago
Kura Oncology To Feature Updated Phase 1a Results From Ongoing FIT-001 Phase 1a/1b Clinical Trial Evaluating Darlifarnib In Combination With Cabozantinib In Advanced Renal Cell Carcinoma In Oral Presentation At 2026 KCRS
Benzinga · 5d ago
Kura Oncology announces availability of press release on darlifarnib-cabozantinib RCC data update
PUBT · 5d ago
Kura Oncology shares long-term FIT-001 data on darlifarnib-cabozantinib combo in advanced kidney cancer at KCRS 2026
PUBT · 5d ago
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
Barchart · 5d ago
Weekly Report: what happened at KURA last week (0706-0710)?
Weekly Report · 6d ago
Kura Oncology (KURA) Is Up 9.3% After Shift From Russell Value To Growth Indices - What's Changed
Simply Wall St · 07/08 14:37
More
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.

Webull offers Kura Oncology Inc stock information, including NASDAQ: KURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KURA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KURA stock methods without spending real money on the virtual paper trading platform.